Redwood Pharma to present at BioStock Investor Meeting in Stockholm on 14th of Sep. 2022
Redwood Pharma will participate in the BioStock Investor Meeting in Stockholm. CEO Martin Vidaeus will update the market about i.e. developments regarding its products in development including the medical device RP501 which is nearing market clearance/approval.
To join the presentation in person, please register at the following link:
The number of slots are limited and pre-registration is required – register now to secure your spot!
The presentation inlcuding a question and answers period will be live-streamed through the BioStock website: www.biostock.se
The presentation will be held in English.
See you on September 14!
About Redwood Pharma
Redwood Pharma AB (publ) (Nasdaq First North Growth Market: REDW) develops next-generation treatments for dry eye. More than 300 million people suffer from dry eyes and today’s standard treatment provides only temporary relief and may need to be applied more than ten times a day. Redwood Pharma’s project is based on IntelliGel – a patented and unique formulation of polymers and water that has the consistency of a drop of water when dropped into the eye, where it immediately forms a viscous, protective and lubricating film that remains for a long time. The company is currently pursuing two development projects: RP501 as a readily available medical device for the treatment of mild dry eye, and the drug candidate RP101 that contains estrogen for the treatment of women who suffer from dry eye after menopause. The company’s Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm (+46 8 463 80 00, email@example.com). For more information, visit www.redwoodpharma.se